Tirzepatide for adolescent obesity: significant benefits, unanswered questions
A study of 160 adolescents shows a significant reduction in BMI with tirzepatide, but also frequent gastrointestinal symptoms. What remains unknown.

Tirzepatide, alongside support for diet and physical activity, significantly reduced body mass index in adolescents with obesity in a 72-week study. Measures related to health and daily functioning also improved. However, side effects were common, and the results do not yet answer questions about long-term use during growth and development.
What the evidence shows
The SURMOUNT-ADOLESCENTS study, published in JAMA, included 160 adolescents aged 12 to under 18 years. It was conducted at 31 centers in Canada, the Czech Republic, Israel, Italy, Poland and the United States, not in Greece. Most participants had severe obesity, and the average age was 14.6 years.
After 12 weeks of initial lifestyle support, 109 adolescents were assigned to tirzepatide and 51 to a placebo, a treatment with no active ingredient. Both groups continued to receive counseling on diet and physical activity.
Body mass index, or BMI, combines weight and height. In children and adolescents, it is assessed in relation to age and sex. At 72 weeks, it had decreased by an average of 18.5% with tirzepatide, while it had increased by 0.5% with placebo. This refers to a change in BMI, not an equivalent percentage loss of body weight.
To make the comparison easier to understand, about 54 in 100 participants in the tirzepatide group were now below the threshold for classification as having obesity, compared with 7 in 100 in the comparison group. About 48 in 100 achieved a BMI reduction of at least 20%, compared with 8 in 100. These figures are conversions of the reported percentages, not the actual numbers of participants in the groups.
Improvements were also recorded in blood pressure, blood glucose, blood lipids and questionnaire scores for physical comfort and quality of life. On the other hand, gastrointestinal symptoms were reported in about 82 in 100 participants receiving tirzepatide and 55 in 100 receiving placebo. Ten of the 108 adolescents who received at least one dose of tirzepatide stopped treatment because of side effects, compared with none in the comparison group.
How certain are the findings?
This was a randomized, double-blind trial: treatment was assigned at random, and neither the participants nor the researchers knew which treatment each participant was receiving. This makes the comparison more reliable than a simple observational study.
However, important limitations remain. A sample of 160 participants is too small to identify rare side effects. A 72-week period does not show what happens over many years. Limited racial and ethnic diversity also makes it harder to generalize the results.
No apparent disruption of growth in height or progression through puberty was observed during the trial. This is reassuring, but it does not establish long-term safety. The data primarily concern obesity and do not support widespread drug treatment for overweight. Funding is not reported in the available material.
Our view
We believe the important finding is not just the change in BMI, but its combination with better functioning and more favorable health measures. We do not yet know whether these changes translate into fewer diseases many years later.
In our view, the results strengthen the case for discussing individualized treatment, not for automatically prescribing it to every adolescent. Nutritional adequacy, growth and development, the relationship with food and side effects must all be taken into account. The publication alone does not constitute a new approval or a change in recommendations in Greece.
What this means for you
- If you are concerned about your child’s weight, seek a comprehensive assessment from a pediatrician or an appropriate specialist team, rather than an interpretation of a number on the scales.
- Maintain a supportive approach, without pressure for rapid weight loss. In the study, nutritional support and physical activity accompanied treatment.
- Do not start or change medication based on these results. Adolescents need individualized medical guidance.
- If treatment is already underway, discuss any gastrointestinal symptoms, difficulty eating or changes in functioning with the doctor. Monitoring should not be limited to weight.
This article is for informational purposes and does not replace your doctor’s advice.
This article is for information only and does not replace an examination and advice from your doctor.

